183 related articles for article (PubMed ID: 38688579)
21. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.
Weathers SP; Penas-Prado M; Pei BL; Ling X; Kassab C; Banerjee P; Bdiwi M; Shaim H; Alsuliman A; Shanley M; de Groot JF; O'Brien BJ; Harrison R; Majd N; Kamiya-Matsuoka C; Fuller GN; Huse JT; Chi L; Rao G; Weinberg JS; Lang FF; Sawaya R; Shpall EJ; Rezvani K; Heimberger AB
Clin Cancer Res; 2020 Jul; 26(14):3565-3577. PubMed ID: 32299815
[TBL] [Abstract][Full Text] [Related]
22. Strong and sustained effector function of memory- versus naïve-derived T cells upon T-cell receptor RNA transfer: implications for cellular therapy.
Thomas S; Klobuch S; Besold K; Plachter B; Dörrie J; Schaft N; Theobald M; Herr W
Eur J Immunol; 2012 Dec; 42(12):3442-53. PubMed ID: 22930221
[TBL] [Abstract][Full Text] [Related]
23. Cytomegalovirus infection of glioblastoma cells leads to NF-κB dependent upregulation of the c-MET oncogenic tyrosine kinase.
Krenzlin H; Zdioruk M; Nowicki MO; Finkelberg T; Keric N; Lemmermann N; Skubal M; Chiocca EA; Cook CH; Lawler SE
Cancer Lett; 2021 Aug; 513():26-35. PubMed ID: 33989707
[TBL] [Abstract][Full Text] [Related]
24. Human cytomegalovirus-mediated immunomodulation: Effects on glioblastoma progression.
Foster H; Ulasov IV; Cobbs CS
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):273-276. PubMed ID: 28554666
[TBL] [Abstract][Full Text] [Related]
25. Abundant cytomegalovirus (CMV) reactive clonotypes in the CD8(+) T cell receptor alpha repertoire following allogeneic transplantation.
Link CS; Eugster A; Heidenreich F; Rücker-Braun E; Schmiedgen M; Oelschlägel U; Kühn D; Dietz S; Fuchs Y; Dahl A; Domingues AM; Klesse C; Schmitz M; Ehninger G; Bornhäuser M; Schetelig J; Bonifacio E
Clin Exp Immunol; 2016 Jun; 184(3):389-402. PubMed ID: 26800118
[TBL] [Abstract][Full Text] [Related]
26. IGFBP2 promotes immunosuppression associated with its mesenchymal induction and FcγRIIB phosphorylation in glioblastoma.
Liu Y; Song C; Shen F; Zhang J; Song SW
PLoS One; 2019; 14(9):e0222999. PubMed ID: 31560714
[TBL] [Abstract][Full Text] [Related]
27. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM.
Ge H; Mu L; Jin L; Yang C; Chang YE; Long Y; DeLeon G; Deleyrolle L; Mitchell DA; Kubilis PS; Lu D; Qi J; Gu Y; Lin Z; Huang J
Int J Cancer; 2017 Oct; 141(7):1434-1444. PubMed ID: 28612394
[TBL] [Abstract][Full Text] [Related]
28. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
[TBL] [Abstract][Full Text] [Related]
29. Modification of Extracellular Matrix Enhances Oncolytic Adenovirus Immunotherapy in Glioblastoma.
Kiyokawa J; Kawamura Y; Ghouse SM; Acar S; Barçın E; Martínez-Quintanilla J; Martuza RL; Alemany R; Rabkin SD; Shah K; Wakimoto H
Clin Cancer Res; 2021 Feb; 27(3):889-902. PubMed ID: 33257429
[TBL] [Abstract][Full Text] [Related]
30. CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment.
Seyfrid M; Maich WT; Shaikh VM; Tatari N; Upreti D; Piyasena D; Subapanditha M; Savage N; McKenna D; Mikolajewicz N; Han H; Chokshi C; Kuhlmann L; Khoo A; Salim SK; Archibong-Bassey B; Gwynne W; Brown K; Murtaza N; Bakhshinyan D; Vora P; Venugopal C; Moffat J; Kislinger T; Singh S
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35017149
[TBL] [Abstract][Full Text] [Related]
31. CMV Status Drives Distinct Trajectories of CD4+ T Cell Differentiation.
Zhang W; Morris AB; Peek EV; Karadkhele G; Robertson JM; Kissick HT; Larsen CP
Front Immunol; 2021; 12():620386. PubMed ID: 33936035
[TBL] [Abstract][Full Text] [Related]
32. Is CMV a target in pediatric glioblastoma? Expression of CMV proteins, pp65 and IE1-72 and CMV nucleic acids in a cohort of pediatric glioblastoma patients.
Wakefield A; Pignata A; Ghazi A; Ashoori A; Hegde M; Landi D; Gray T; Scheurer ME; Chintagumpala M; Adesina A; Gottschalk S; Hicks J; Powell SZ; Ahmed N
J Neurooncol; 2015 Nov; 125(2):307-15. PubMed ID: 26341370
[TBL] [Abstract][Full Text] [Related]
33. Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.
Lamano JB; Lamano JB; Li YD; DiDomenico JD; Choy W; Veliceasa D; Oyon DE; Fakurnejad S; Ampie L; Kesavabhotla K; Kaur R; Kaur G; Biyashev D; Unruh DJ; Horbinski CM; James CD; Parsa AT; Bloch O
Clin Cancer Res; 2019 Jun; 25(12):3643-3657. PubMed ID: 30824583
[TBL] [Abstract][Full Text] [Related]
34. Different T-cell subsets in glioblastoma multiforme and targeted immunotherapy.
Wang H; Zhou H; Xu J; Lu Y; Ji X; Yao Y; Chao H; Zhang J; Zhang X; Yao S; Wu Y; Wan J
Cancer Lett; 2021 Jan; 496():134-143. PubMed ID: 33022290
[TBL] [Abstract][Full Text] [Related]
35. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of pp65-specific TCR-T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation.
Liu G; Chen H; Cao X; Jia L; Rui W; Zheng H; Huang D; Liu F; Liu Y; Zhao X; Lu P; Lin X
Am J Hematol; 2022 Nov; 97(11):1453-1463. PubMed ID: 36054234
[TBL] [Abstract][Full Text] [Related]
37. Integrated single-cell transcriptomic analyses reveal that GPNMB-high macrophages promote PN-MES transition and impede T cell activation in GBM.
Xiong A; Zhang J; Chen Y; Zhang Y; Yang F
EBioMedicine; 2022 Sep; 83():104239. PubMed ID: 36054938
[TBL] [Abstract][Full Text] [Related]
38. Refining human T-cell immunotherapy of cytomegalovirus disease: a mouse model with 'humanized' antigen presentation as a new preclinical study tool.
Lemmermann NA; Reddehase MJ
Med Microbiol Immunol; 2016 Dec; 205(6):549-561. PubMed ID: 27539576
[TBL] [Abstract][Full Text] [Related]
39. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
40. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
